Pazopanib for the treatment of metastatic renal cell carcinoma

Clinical Therapeutics

Volumn 34, Issue 3, 2012, Pages 511-520

  Pick, Amy M ^a   Nystrom, Kelly K ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

Adverse events; Pazopanib; Renal cell carcinoma; Therapeutic use

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYTOCHROME P450 3A4; EVEROLIMUS; LAPATINIB; PACLITAXEL; PAZOPANIB; PLACEBO; RECOMBINANT INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; DEPIGMENTATION; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; HAIR DEPIGMENTATION; HAIR DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MEDLINE; NAUSEA; NEUTROPENIA; PROGRESSION FREE SURVIVAL; QT PROLONGATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THERAPY EFFECT; THROMBOCYTOPENIA; TORSADE DES POINTES; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84858609640     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.01.014     Document Type: Review

References (25)

1. Cohen H., McGovern F. Renal cell carcinoma. N Engl J Med 2005, 353:3477-3490.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 61:10-29.
3. National Comprehensive Cancer Network Practice Guidelines. Kidney Cancer Accessed January 11, 2012. http://www.nccn.org.
4. Linehan W.M., Bates S.E., Yang J.C. Cancers of the genitorurinary system: cancer of the kidney. Cancer: Principles and Practice of Oncology 2006, 1139-1168. Lippincott, Philadelphia, Pa. V.T. Devita, S. Hellman, S.A. Rosenberg (Eds.).
5. Reeves D.J., Liu C.Y. Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2009, 64:11-25.
6. Lainakis G., Bamias A. Targeting angiogenesis in renal cell carcinoma. Curr Cancer Drug Targets 2008, 8:349-358.
7. Kidney. American Joint Committee on Cancer: AJCC Cancer Staging Manual 2002, 323-325. Springer, New York, NY. 6th ed.
8. Clark J.I., Atkins M.B., Urba W.J., et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003, 21:3133-3140.
9. Messing E.M., Manola J., Wilding G., et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003, 21:1214-1222.
10. Fossa S.D. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000, 27:187-193.
11. Coppin C., Porzsolt F., Awa A., et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005, 1. CD001425.
12. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 225 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13:688-696.
13. Votrient (pazopanib) 2011, [package insert], GlaxoSmithKline, Research Triangle Park, NC.
14. Sonpavde G., Hutson T.E. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007, 9:115-119.
15. Hurwitz H.I., Dowlati A., Saini S., et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009, 15:4220-4227.
16. Highlights of Prescribing Information. Votrient (pazopanib) tablets US Food and Drug Administration, Accessed January 11, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022465s003s005lbl.pdf.
17. CHMP assessment report Votrient European Medicines Agency, Accessed January 11, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001141/WC500094275.pdf.
18. Limvorasak S., Posadas E.M. Pazopanib: therapeutics developments. Expert Opin Pharmacother 2009, 10:3091-3102.
19. Hutson T.E., Davis I.D., Machiels J.P., et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010, 28:475-480.
20. Therasse R., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
21. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
22. Sutent (sunitinib) 2008, [package insert], Pfizer Inc, New York, NY.
23. Hawkins R., Hodge R., Chen M., et al. Renal cancer quality of life (QOL) in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) treated with pazopanib: results from a phase III double-blind, placebo-controlled trial. EJC Supplements 2009, 7:428-429.
24. Nexavar (sorafenib) 2008, [package insert], Bayer Pharmaceuticals Corp, West Haven, Conn.
25. Red Book Online Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc., Accessed January 9, 2012. http://www-thomsonhc-com.cuhsl.creighton.edu/micromedex2/librarian.